PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 6 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Mukungulu extract robustly reversed latency in ART-suppressed HIV-infected humanized mice at 5 mg/kg and reversed latency in primary cells from ART-suppressed people living with HIV-1 at 1 µg/mL [PMID:40265896].
Bark extracts inhibited the replication of wild-type (NL4.3) HIV-1 in vitro in a dose-dependent manner [PMID:27350006].
Methanolic extracts showed antibacterial activity against Enterococcus faecalis (MIC 0.02 mg/ml) and acetone fractions showed activity against Pseudomonas aeruginosa (MIC 0.06 mg/ml) [PMID:21304619].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 10616956 (1999) — Traditional healers and the treatment of sexually transmitted illnesses in rural Zambia. · Journal of ethnopharmacology
- 2.PMID: 40265896 (2025) — Ex vivo and in vivo HIV-1 latency reversal by "Mukungulu," a protein kinase C-activating African medicinal plant extract. · mBio
- 3.PMID: 27350006 (2016) — Croton megalobotrys Müll Arg. and Vitex doniana (Sweet): Traditional medicinal plants in a three-step treatment regimen that inhibit in vitro replication of HIV-1. · Journal of ethnopharmacology
- 4.PMID: 21304619 (2009) — Antibacterial activity of extracts of three Croton species collected in Mpumalanga region in South Africa. · African journal of traditional, complementary, and alternative medicines : AJTCAM
- 5.PMID: 28970153